Company / PP&E (Net)
Bristol Myers Squibb PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$7.5B
FY2025
5-year range
$6.0B / $7.5B
FY2021-FY2025
Trend
+5.7%
vs FY2024
Sector context
#6 of 193
Health Care
What the data says
Among 193 Health Care companies, Bristol Myers Squibb is in the top 3% for pp&e (net). PP&E (Net) has increased for 5 consecutive years, from $5.9B in FY2020 to $7.5B in FY2025.
Based on SEC 10-K filings.
$7.5B in FY2025 with a 5-year CAGR of +5.1%. Top quartile in the Health Care sector.
Improved from $6.6B to $7.5B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +6.4%
- 5-Year CAGR
- +5.1%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 193This company $7.5B Sector average $777.6M
▼
+870.0% above sector average
Key checks
Key Insights
- Bristol Myers Squibb's pp&e (net) has grown for 5 consecutive years.
- 5-year CAGR of +5.1%, indicating consistent growth.
- In FY2025, pp&e (net) increased 5.7% year-over-year.
- Ranks #6 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.5B | +5.7% |
| FY2024 | $7.1B | +7.4% |
| FY2023 | $6.6B | +6.3% |
| FY2022 | $6.3B | +3.4% |
| FY2021 | $6.0B | +2.8% |
| FY2020 | $5.9B | -5.9% |
| FY2019 | $6.3B | +24.4% |
| FY2018 | $5.0B | +0.5% |
| FY2017 | $5.0B | +0.4% |
| FY2016 | $5.0B | +12.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026